Pirfenidone (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pirfenidone" in Italian language version.

refsWebsite

Global rank Italian rank

30nih.gov

4^th place

9^th place

21doi.org

2^nd place

7^th place

20oadoi.org

799^th place

22^nd place

1web.archive.org

1^st place

1worldcat.org

5^th place

26^th place

1unibo.it

4,963^rd place

325^th place

1doai.io

low place

3,405^th place

1ilsole24ore.com

1,027^th place

44^th place

doai.io

P. Spagnolo, C. Del Giovane; F. Luppi; S. Cerri; S. Balduzzi; EH. Walters; R. D'Amico; L. Richeldi, Non-steroid agents for idiopathic pulmonary fibrosis., in Cochrane Database Syst Rev, n. 9, 2010, pp. CD003134, DOI:10.1002/14651858.CD003134.pub2, PMID 20824834.

doi.org

dx.doi.org

Luca Richeldi, Uma Yasothan e Peter Kirkpatrick, Pirfenidone, in Nature Reviews Drug Discovery, vol. 10, n. 7, 2011, pp. 475–476, DOI:10.1038/nrd3495, ISSN 1474-1776 (WC · ACNP).
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K, Antifibrotic activities of pirfenidone in animal models, in Eur Respir Rev, vol. 20, n. 120, giugno 2011, pp. 85–97, DOI:10.1183/09059180.00001111, PMID 21632796.
Lin X, Yu M, Wu K, Yuan H, Zhong H, Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro, in Invest. Ophthalmol. Vis. Sci., vol. 50, n. 8, agosto 2009, pp. 3763–70, DOI:10.1167/iovs.08-2815, PMID 19264889.
Nakayama S, Mukae H, Sakamoto N, et al., Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts, in Life Sci., vol. 82, n. 3-4, gennaio 2008, pp. 210–7, DOI:10.1016/j.lfs.2007.11.003, PMID 18093617.
Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB, Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro, in Int. Immunopharmacol., vol. 8, n. 5, maggio 2008, pp. 679–87, DOI:10.1016/j.intimp.2008.01.013, PMID 18387510.
H. Oku, T. Shimizu; T. Kawabata; M. Nagira; I. Hikita; A. Ueyama; S. Matsushima; M. Torii; A. Arimura, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis., in Eur J Pharmacol, vol. 590, n. 1-3, agosto 2008, pp. 400-8, DOI:10.1016/j.ejphar.2008.06.046, PMID 18598692.
JW. Card, WJ. Racz; JF. Brien; SB. Margolin; TE. Massey, Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity., in Toxicol Sci, vol. 75, n. 1, settembre 2003, pp. 169-80, DOI:10.1093/toxsci/kfg167, PMID 12832656.
H. Liu, P. Drew; AC. Gaugler; Y. Cheng; GA. Visner, Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway., in Am J Transplant, vol. 5, n. 6, giugno 2005, pp. 1256-63, DOI:10.1111/j.1600-6143.2005.00876.x, PMID 15888029.
H. Zhou, CW. Latham; DS. Zander; SB. Margolin; GA. Visner, Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts., in J Heart Lung Transplant, vol. 24, n. 10, ottobre 2005, pp. 1577-85, DOI:10.1016/j.healun.2004.11.002, PMID 16210133.
A. Hirano, A. Kanehiro; K. Ono; W. Ito; A. Yoshida; C. Okada; H. Nakashima; Y. Tanimoto; M. Kataoka; EW. Gelfand; M. Tanimoto, Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge., in Am J Respir Cell Mol Biol, vol. 35, n. 3, settembre 2006, pp. 366-77, DOI:10.1165/rcmb.2005-0452OC, PMID 16675785.
SN. Iyer, SB. Margolin; DM. Hyde; SN. Giri, Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model., in Exp Lung Res, vol. 24, n. 1, pp. 119-32, DOI:10.3109/01902149809046058, PMID 9457473.
KW. Lee, TH. Everett; D. Rahmutula; JM. Guerra; E. Wilson; C. Ding; JE. Olgin, Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure., in Circulation, vol. 114, n. 16, ottobre 2006, pp. 1703-12, DOI:10.1161/CIRCULATIONAHA.106.624320, PMID 17030685.
DT. Nguyen, C. Ding; E. Wilson; GM. Marcus; JE. Olgin, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias., in Heart Rhythm, vol. 7, n. 10, ottobre 2010, pp. 1438-45, DOI:10.1016/j.hrthm.2010.04.030, PMID 20433946.
S. Mirkovic, AM. Seymour; A. Fenning; A. Strachan; SB. Margolin; SM. Taylor; L. Brown, Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats., in Br J Pharmacol, vol. 135, n. 4, febbraio 2002, pp. 961-8, DOI:10.1038/sj.bjp.0704539, PMID 11861324.
T. Shimizu, T. Kuroda; S. Hata; M. Fukagawa; SB. Margolin; K. Kurokawa, Pirfenidone improves renal function and fibrosis in the post-obstructed kidney., in Kidney Int, vol. 54, n. 1, luglio 1998, pp. 99-109, DOI:10.1046/j.1523-1755.1998.00XXX.x, PMID 9648068.
K. Takakuta, A. Fujimori; T. Chikanishi; A. Tanokura; Y. Iwatsuki; M. Yamamoto; H. Nakajima; M. Okada; H. Itoh, Renoprotective properties of pirfenidone in subtotally nephrectomized rats., in Eur J Pharmacol, vol. 629, n. 1-3, marzo 2010, pp. 118-24, DOI:10.1016/j.ejphar.2009.12.011, PMID 20006961.
A. Salazar-Montes, L. Ruiz-Corro; A. López-Reyes; E. Castrejón-Gómez; J. Armendáriz-Borunda, Potent antioxidant role of pirfenidone in experimental cirrhosis., in Eur J Pharmacol, vol. 595, n. 1-3, ottobre 2008, pp. 69-77, DOI:10.1016/j.ejphar.2008.06.110, PMID 18652820.
Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS, Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults, in Pulm Pharmacol Ther, vol. 22, n. 4, agosto 2009, pp. 279–85, DOI:10.1016/j.pupt.2009.03.003, PMID 19328861.
H. Taniguchi, M. Ebina; Y. Kondoh; T. Ogura; A. Azuma; M. Suga; Y. Taguchi; H. Takahashi; K. Nakata; A. Sato; M. Takeuchi, Pirfenidone in idiopathic pulmonary fibrosis., in Eur Respir J, vol. 35, n. 4, aprile 2010, pp. 821-9, DOI:10.1183/09031936.00005209, PMID 19996196.
PW. Noble, C. Albera; WZ. Bradford; U. Costabel; MK. Glassberg; D. Kardatzke; TE. King; L. Lancaster; SA. Sahn; J. Szwarcberg; D. Valeyre, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials., in Lancet, vol. 377, n. 9779, maggio 2011, pp. 1760-9, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
P. Spagnolo, C. Del Giovane; F. Luppi; S. Cerri; S. Balduzzi; EH. Walters; R. D'Amico; L. Richeldi, Non-steroid agents for idiopathic pulmonary fibrosis., in Cochrane Database Syst Rev, n. 9, 2010, pp. CD003134, DOI:10.1002/14651858.CD003134.pub2, PMID 20824834.

ilsole24ore.com

system24.ilsole24ore.com

http://www.system24.ilsole24ore.com/static/minisiti/2013/bside/251113_LMB_biotecnologia_chimica_e_farmaceutica/Pagine/5.pdf.

nih.gov

ncbi.nlm.nih.gov

Lasky J, Pirfenidone, in IDrugs, vol. 7, n. 2, febbraio 2004, pp. 166–72, PMID 15057662.
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K, Antifibrotic activities of pirfenidone in animal models, in Eur Respir Rev, vol. 20, n. 120, giugno 2011, pp. 85–97, DOI:10.1183/09059180.00001111, PMID 21632796.
Di Sario A, Bendia E, Svegliati Baroni G, et al., Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production, in J. Hepatol., vol. 37, n. 5, novembre 2002, pp. 584–91, PMID 12399223.
Hewitson TD, Kelynack KJ, Tait MG, et al., Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis, in J. Nephrol., vol. 14, n. 6, 2001, pp. 453–60, PMID 11783601.
Lin X, Yu M, Wu K, Yuan H, Zhong H, Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro, in Invest. Ophthalmol. Vis. Sci., vol. 50, n. 8, agosto 2009, pp. 3763–70, DOI:10.1167/iovs.08-2815, PMID 19264889.
Lee BS, Margolin SB, Nowak RA, Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production, in J. Clin. Endocrinol. Metab., vol. 83, n. 1, gennaio 1998, pp. 219–23, PMID 9435445.
Nakayama S, Mukae H, Sakamoto N, et al., Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts, in Life Sci., vol. 82, n. 3-4, gennaio 2008, pp. 210–7, DOI:10.1016/j.lfs.2007.11.003, PMID 18093617.
Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB, Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro, in Int. Immunopharmacol., vol. 8, n. 5, maggio 2008, pp. 679–87, DOI:10.1016/j.intimp.2008.01.013, PMID 18387510.
T. Kakugawa, H. Mukae; T. Hayashi; H. Ishii; K. Abe; T. Fujii; H. Oku; M. Miyazaki; J. Kadota; S. Kohno, Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis., in Eur Respir J, vol. 24, n. 1, luglio 2004, pp. 57-65, PMID 15293605.
H. Oku, T. Shimizu; T. Kawabata; M. Nagira; I. Hikita; A. Ueyama; S. Matsushima; M. Torii; A. Arimura, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis., in Eur J Pharmacol, vol. 590, n. 1-3, agosto 2008, pp. 400-8, DOI:10.1016/j.ejphar.2008.06.046, PMID 18598692.
JW. Card, WJ. Racz; JF. Brien; SB. Margolin; TE. Massey, Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity., in Toxicol Sci, vol. 75, n. 1, settembre 2003, pp. 169-80, DOI:10.1093/toxsci/kfg167, PMID 12832656.
H. Liu, P. Drew; AC. Gaugler; Y. Cheng; GA. Visner, Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway., in Am J Transplant, vol. 5, n. 6, giugno 2005, pp. 1256-63, DOI:10.1111/j.1600-6143.2005.00876.x, PMID 15888029.
H. Zhou, CW. Latham; DS. Zander; SB. Margolin; GA. Visner, Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts., in J Heart Lung Transplant, vol. 24, n. 10, ottobre 2005, pp. 1577-85, DOI:10.1016/j.healun.2004.11.002, PMID 16210133.
A. Hirano, A. Kanehiro; K. Ono; W. Ito; A. Yoshida; C. Okada; H. Nakashima; Y. Tanimoto; M. Kataoka; EW. Gelfand; M. Tanimoto, Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge., in Am J Respir Cell Mol Biol, vol. 35, n. 3, settembre 2006, pp. 366-77, DOI:10.1165/rcmb.2005-0452OC, PMID 16675785.
SN. Iyer, JS. Wild; MJ. Schiedt; DM. Hyde; SB. Margolin; SN. Giri, Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters., in J Lab Clin Med, vol. 125, n. 6, giugno 1995, pp. 779-85, PMID 7539478.
SN. Iyer, SB. Margolin; DM. Hyde; SN. Giri, Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model., in Exp Lung Res, vol. 24, n. 1, pp. 119-32, DOI:10.3109/01902149809046058, PMID 9457473.
SN. Iyer, G. Gurujeyalakshmi; SN. Giri, Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis., in J Pharmacol Exp Ther, vol. 289, n. 1, aprile 1999, pp. 211-8, PMID 10087006.
KW. Lee, TH. Everett; D. Rahmutula; JM. Guerra; E. Wilson; C. Ding; JE. Olgin, Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure., in Circulation, vol. 114, n. 16, ottobre 2006, pp. 1703-12, DOI:10.1161/CIRCULATIONAHA.106.624320, PMID 17030685.
DT. Nguyen, C. Ding; E. Wilson; GM. Marcus; JE. Olgin, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias., in Heart Rhythm, vol. 7, n. 10, ottobre 2010, pp. 1438-45, DOI:10.1016/j.hrthm.2010.04.030, PMID 20433946.
S. Mirkovic, AM. Seymour; A. Fenning; A. Strachan; SB. Margolin; SM. Taylor; L. Brown, Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats., in Br J Pharmacol, vol. 135, n. 4, febbraio 2002, pp. 961-8, DOI:10.1038/sj.bjp.0704539, PMID 11861324.
T. Shimizu, T. Kuroda; S. Hata; M. Fukagawa; SB. Margolin; K. Kurokawa, Pirfenidone improves renal function and fibrosis in the post-obstructed kidney., in Kidney Int, vol. 54, n. 1, luglio 1998, pp. 99-109, DOI:10.1046/j.1523-1755.1998.00XXX.x, PMID 9648068.
K. Takakuta, A. Fujimori; T. Chikanishi; A. Tanokura; Y. Iwatsuki; M. Yamamoto; H. Nakajima; M. Okada; H. Itoh, Renoprotective properties of pirfenidone in subtotally nephrectomized rats., in Eur J Pharmacol, vol. 629, n. 1-3, marzo 2010, pp. 118-24, DOI:10.1016/j.ejphar.2009.12.011, PMID 20006961.
A. Salazar-Montes, L. Ruiz-Corro; A. López-Reyes; E. Castrejón-Gómez; J. Armendáriz-Borunda, Potent antioxidant role of pirfenidone in experimental cirrhosis., in Eur J Pharmacol, vol. 595, n. 1-3, ottobre 2008, pp. 69-77, DOI:10.1016/j.ejphar.2008.06.110, PMID 18652820.
L. García, I. Hernández; A. Sandoval; A. Salazar; J. Garcia; J. Vera; G. Grijalva; P. Muriel; S. Margolin; J. Armendariz-Borunda, Pirfenidone effectively reverses experimental liver fibrosis., in J Hepatol, vol. 37, n. 6, dicembre 2002, pp. 797-805, PMID 12445421.
Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS, Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults, in Pulm Pharmacol Ther, vol. 22, n. 4, agosto 2009, pp. 279–85, DOI:10.1016/j.pupt.2009.03.003, PMID 19328861.
Taniyama M, Ohbayashi S, Narita M, et al., Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients, in Eur. J. Clin. Pharmacol., vol. 52, n. 1, 1997, pp. 77–8, PMID 9143872.
H. Taniguchi, M. Ebina; Y. Kondoh; T. Ogura; A. Azuma; M. Suga; Y. Taguchi; H. Takahashi; K. Nakata; A. Sato; M. Takeuchi, Pirfenidone in idiopathic pulmonary fibrosis., in Eur Respir J, vol. 35, n. 4, aprile 2010, pp. 821-9, DOI:10.1183/09031936.00005209, PMID 19996196.
PW. Noble, C. Albera; WZ. Bradford; U. Costabel; MK. Glassberg; D. Kardatzke; TE. King; L. Lancaster; SA. Sahn; J. Szwarcberg; D. Valeyre, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials., in Lancet, vol. 377, n. 9779, maggio 2011, pp. 1760-9, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
P. Spagnolo, C. Del Giovane; F. Luppi; S. Cerri; S. Balduzzi; EH. Walters; R. D'Amico; L. Richeldi, Non-steroid agents for idiopathic pulmonary fibrosis., in Cochrane Database Syst Rev, n. 9, 2010, pp. CD003134, DOI:10.1002/14651858.CD003134.pub2, PMID 20824834.
Filippo Drago, Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure., in Value in Health, vol. 18, n. 1, Gennaio 2015, PMID 25595244.

oadoi.org

Luca Richeldi, Uma Yasothan e Peter Kirkpatrick, Pirfenidone, in Nature Reviews Drug Discovery, vol. 10, n. 7, 2011, pp. 475–476, DOI:10.1038/nrd3495, ISSN 1474-1776 (WC · ACNP).
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K, Antifibrotic activities of pirfenidone in animal models, in Eur Respir Rev, vol. 20, n. 120, giugno 2011, pp. 85–97, DOI:10.1183/09059180.00001111, PMID 21632796.
Lin X, Yu M, Wu K, Yuan H, Zhong H, Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro, in Invest. Ophthalmol. Vis. Sci., vol. 50, n. 8, agosto 2009, pp. 3763–70, DOI:10.1167/iovs.08-2815, PMID 19264889.
Nakayama S, Mukae H, Sakamoto N, et al., Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts, in Life Sci., vol. 82, n. 3-4, gennaio 2008, pp. 210–7, DOI:10.1016/j.lfs.2007.11.003, PMID 18093617.
Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB, Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro, in Int. Immunopharmacol., vol. 8, n. 5, maggio 2008, pp. 679–87, DOI:10.1016/j.intimp.2008.01.013, PMID 18387510.
H. Oku, T. Shimizu; T. Kawabata; M. Nagira; I. Hikita; A. Ueyama; S. Matsushima; M. Torii; A. Arimura, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis., in Eur J Pharmacol, vol. 590, n. 1-3, agosto 2008, pp. 400-8, DOI:10.1016/j.ejphar.2008.06.046, PMID 18598692.
JW. Card, WJ. Racz; JF. Brien; SB. Margolin; TE. Massey, Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity., in Toxicol Sci, vol. 75, n. 1, settembre 2003, pp. 169-80, DOI:10.1093/toxsci/kfg167, PMID 12832656.
H. Liu, P. Drew; AC. Gaugler; Y. Cheng; GA. Visner, Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway., in Am J Transplant, vol. 5, n. 6, giugno 2005, pp. 1256-63, DOI:10.1111/j.1600-6143.2005.00876.x, PMID 15888029.
H. Zhou, CW. Latham; DS. Zander; SB. Margolin; GA. Visner, Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts., in J Heart Lung Transplant, vol. 24, n. 10, ottobre 2005, pp. 1577-85, DOI:10.1016/j.healun.2004.11.002, PMID 16210133.
A. Hirano, A. Kanehiro; K. Ono; W. Ito; A. Yoshida; C. Okada; H. Nakashima; Y. Tanimoto; M. Kataoka; EW. Gelfand; M. Tanimoto, Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge., in Am J Respir Cell Mol Biol, vol. 35, n. 3, settembre 2006, pp. 366-77, DOI:10.1165/rcmb.2005-0452OC, PMID 16675785.
SN. Iyer, SB. Margolin; DM. Hyde; SN. Giri, Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model., in Exp Lung Res, vol. 24, n. 1, pp. 119-32, DOI:10.3109/01902149809046058, PMID 9457473.
KW. Lee, TH. Everett; D. Rahmutula; JM. Guerra; E. Wilson; C. Ding; JE. Olgin, Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure., in Circulation, vol. 114, n. 16, ottobre 2006, pp. 1703-12, DOI:10.1161/CIRCULATIONAHA.106.624320, PMID 17030685.
DT. Nguyen, C. Ding; E. Wilson; GM. Marcus; JE. Olgin, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias., in Heart Rhythm, vol. 7, n. 10, ottobre 2010, pp. 1438-45, DOI:10.1016/j.hrthm.2010.04.030, PMID 20433946.
S. Mirkovic, AM. Seymour; A. Fenning; A. Strachan; SB. Margolin; SM. Taylor; L. Brown, Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats., in Br J Pharmacol, vol. 135, n. 4, febbraio 2002, pp. 961-8, DOI:10.1038/sj.bjp.0704539, PMID 11861324.
T. Shimizu, T. Kuroda; S. Hata; M. Fukagawa; SB. Margolin; K. Kurokawa, Pirfenidone improves renal function and fibrosis in the post-obstructed kidney., in Kidney Int, vol. 54, n. 1, luglio 1998, pp. 99-109, DOI:10.1046/j.1523-1755.1998.00XXX.x, PMID 9648068.
K. Takakuta, A. Fujimori; T. Chikanishi; A. Tanokura; Y. Iwatsuki; M. Yamamoto; H. Nakajima; M. Okada; H. Itoh, Renoprotective properties of pirfenidone in subtotally nephrectomized rats., in Eur J Pharmacol, vol. 629, n. 1-3, marzo 2010, pp. 118-24, DOI:10.1016/j.ejphar.2009.12.011, PMID 20006961.
A. Salazar-Montes, L. Ruiz-Corro; A. López-Reyes; E. Castrejón-Gómez; J. Armendáriz-Borunda, Potent antioxidant role of pirfenidone in experimental cirrhosis., in Eur J Pharmacol, vol. 595, n. 1-3, ottobre 2008, pp. 69-77, DOI:10.1016/j.ejphar.2008.06.110, PMID 18652820.
Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS, Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults, in Pulm Pharmacol Ther, vol. 22, n. 4, agosto 2009, pp. 279–85, DOI:10.1016/j.pupt.2009.03.003, PMID 19328861.
H. Taniguchi, M. Ebina; Y. Kondoh; T. Ogura; A. Azuma; M. Suga; Y. Taguchi; H. Takahashi; K. Nakata; A. Sato; M. Takeuchi, Pirfenidone in idiopathic pulmonary fibrosis., in Eur Respir J, vol. 35, n. 4, aprile 2010, pp. 821-9, DOI:10.1183/09031936.00005209, PMID 19996196.
PW. Noble, C. Albera; WZ. Bradford; U. Costabel; MK. Glassberg; D. Kardatzke; TE. King; L. Lancaster; SA. Sahn; J. Szwarcberg; D. Valeyre, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials., in Lancet, vol. 377, n. 9779, maggio 2011, pp. 1760-9, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.

unibo.it

acnpsearch.unibo.it

Luca Richeldi, Uma Yasothan e Peter Kirkpatrick, Pirfenidone, in Nature Reviews Drug Discovery, vol. 10, n. 7, 2011, pp. 475–476, DOI:10.1038/nrd3495, ISSN 1474-1776 (WC · ACNP).

web.archive.org

(EN) www.cipladoc.com (PDF), su cipladoc.com (archiviato dall'url originale il 13 gennaio 2012).

worldcat.org

Luca Richeldi, Uma Yasothan e Peter Kirkpatrick, Pirfenidone, in Nature Reviews Drug Discovery, vol. 10, n. 7, 2011, pp. 475–476, DOI:10.1038/nrd3495, ISSN 1474-1776 (WC · ACNP).